Alyeska Investment Group
BMY icon

Alyeska Investment Group’s Bristol-Myers Squibb BMY Stock Holding History

Alyeska Investment Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-500,000
Closed -$23.9M – 445
2019
Q1 		$23.9M Buy
+500,000
New +$24.9M 0.32% 105

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Alyeska Investment Group's BMY Position: Q2 2021 in Review

Alyeska Investment Group sold out of Bristol-Myers Squibb (BMY) in Q2 2021, closing a stake of 329,935 shares — an estimated $20.8M sold.

Alyeska Investment Group first reported a position in BMY in Q2 2013 and held it in 16 quarters. The position peaked at $80.2M in Q1 2017. 2,370 funds tracked by Wall St. Rank hold BMY as of Q2 2021.

  • Alyeska Investment Group reported no remaining Bristol-Myers Squibb position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 329,935 Bristol-Myers Squibb shares in Q2 2021, an estimated $20.8M.
  • Alyeska Investment Group first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 16 quarters.
  • Alyeska Investment Group's Bristol-Myers Squibb position peaked at $80.2M in Q1 2017.
  • 2,370 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.